UnknownNot Applicable

Auditory MMN EEG in TRD in Response to Ketamine

Canada30 participantsStarted 2022-10-03

Plain-language summary

To develop and test a neurocomputational model of ketamine treatment response predictions in TRD.

Age range18 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✓.18 to 65 years of age 2. Meeting Diagnostic and Statistical Manual for Mental Disorders (DSM-5) criteria for MDD and in a Major Depressive Episode and ≥10 on the Montgomery-Asberg Depression Rating Scale (MADRS).

✕. History of bipolar disorder or psychosis
✕. Current substance use or history of substance use during the past year (excluding nicotine and caffeine use disorder)
✕. Concomitant major and unstable medical or neurologic illness or a history of seizures.
✕. Non-English-speaking individuals.

Clinical remission

Timeframe: 4 weeks following the baseline visit

NCT IDNCT05464264

SponsorUnity Health Toronto

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2024-10

Venkat Bhat, MD MSc